| Health / Medical Topics |
HLA-A*2402-restricted VEGFR1/2 Multipeptide Vaccine
A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, this peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine containing the HLA-A*2402-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide epitope with potential immunostimulatory and antitumor activities. Upon…
A cancer vacine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from:…
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from URLC10 (up-regulated…
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are…
